Advertisement
Policy Forum

Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies.

See all article types »

Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection

  • Inge Derdelinckx,
  • Mark A Wainberg,
  • Joep M. A Lange,
  • Andrew Hill,
  • Yasmin Halima,
  • Charles A. B Boucher mail

    To whom correspondence should be addressed. E-mail:c.boucher@umcutrecht.nl

    X
  • Published: November 07, 2006
  • DOI: 10.1371/journal.pmed.0030454

About the Authors

Corresponding Author

Email: c.boucher@umcutrecht.nl

Competing Interests

ID received travel grants from Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Roche. MAW declares that he has no competing interests. JAL declares that he has received honoraria for advice, speaking engagements, or research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Roche, and Tibotec. AH has received consultancy payments from Tibotec (Johnson and Johnson). YH received a travel grant to participate in a GlaxoSmithKline advisory board. CABB serves or has served on scientific (HIV) advisory boards, spoken at symposia of, and/or received research grants from the following pharmaceutical companies: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer, and Roche. He declares that he does not own any pharmaceutical company stock. He is a grant holder of various European Community grants for the study of HIV drug resistance and drug resistance transmission. He also serves as a member of the World Health Organization HIV ResNet advisory body and is a member of organising committees of several meetings on HIV.